Background: Based on assessment of mRNA expression, the lung is a major site of expression of the vascular endothelial growth factor (VEGF) gene, largely from type II alveolar epithelial cells. With the knowledge that VEGF can function to induce vascular leak, we hypothesized that to protect the lung from pulmonary edema, the VEGF produced in the lung must be compartmentalized from the pulmonary endothelium, and thus must be compartmentalized to the surface of the respiratory epithelium.
Introduction
Vascular endothelial growth factor (VEGF; also referred to as VEGF-A or VEGF-1), a 34-46 kDa mediator produced by many different cell types, has been intensively studied for its role in blood vessel formation in embryogenesis and for its ability to induce angiogenesis in tissues of both ischemic and nonischemic adults (1) (2) (3) (4) (5) (6) . VEGF is also expressed by many tumor cells and is believed to play a critical role in the ability of tumors to generate an adequate blood supply (3) . The role of VEGF in pathogenic angiogenesis has also been implicated in the generation of hemangiomas and in proliferative retinopathy (3, 5, 7, 8) . Almost forgotten, however, is that one of the original functions discovered for VEGF was its ability to induce vascular leak, i.e., to enhance blood vessel permeability. Originally observed by Senger et al. (9) , when VEGF is injected into the skin of guinea pigs, its permeability function is readily observed as the leak of high molecular weight molecules from the vasculature into the surrounding tissues (1, 9, 10) .
It is well recognized that of all organs, the expression of the VEGF gene at the mRNA level is highest in the lung (11, 12) . In situ studies have demonstrated that the major site of VEGF mRNA expression in the lung is in alveolar type II epithelial cells (13) (14) (15) (16) . Together, however, these observations do not seem consistent. The alveolar structures are very fragile and very sensitive to enhanced permeability of the alveolar vasculature (17) . If the VEGF gene is highly expressed in the lung epithelium and VEGF protein levels in lung are commensurate with VEGF mRNA levels, either the alveolar endothelium does not exhibit vascular leak in response to VEGF or VEGF would have to be compartmentalized to the epithelial surface, where the high levels of VEGF would have to diffuse across the tight alveolar epithelial barrier to reach the pulmonary endothelium. Using adenovirus-mediated transfer of the VEGF165 cDNA, we have recently demonstrated that exposure of the alveolar endothelium to high levels of VEGF results in pulmonary edema, which suggests that VEGF can induce vascular permeability if sufficient amounts reach the pulmonary endothelium (18) .
Based on these observations, we hypothesize that the high level of expression of the VEGF gene in pulmonary epithelium results in compartmentalization of VEGF protein on the epithelial surface of the lower respiratory tract. To test this hypothesis, we have quantified VEGF levels in epithelial lining fluid (ELF) of normal individuals, and compared these levels to the plasma levels in the same individuals. Remarkably, the data demonstrate that pulmonary ELF VEGF levels are 500-fold greater than plasma, i.e., large amounts of VEGF are compartmentalized to the respiratory epithelial surface, an observation that has significant implications in the physiology of the lung in health and disease.
Methods

Bronchoalveolar Lavage
Bronchoalveolar lavage (BAL) to recover epithelial lining fluid of the lower respiratory tract was carried out as previously described (19) . After signing informed consent, normal human nonsmoking volunteers (6 males, 3 females; age 28 Ϯ 4 yr) underwent bronchoscopy with lavage under protocols approved by the Institutional Review Boards of Rockefeller University Hospital and the Weill Medical College of Cornell University. Briefly, a bronchoscope was advanced to a wedged position and five successive 20-mL aliquots of phosphate buffered saline, pH 7.4 (PBS), were instilled into each of three different sites for a total of 300 mL. The fluid was immediately aspirated after each 20-mL aliquot to minimize dwell time (20) . The recovered fluid (average 62%, 185 mL Ϯ 12%) was filtered through gauze to remove debris, the cells were pelleted (300 ϫ g, 5 min), and the supernatant was removed. The cell pellets were resuspended in RPMI 1640 (Life Technologies, Rockville, MD), and an aliquot was counted in a hemacytometer. Cell counts in BAL fluid were (9 Ϯ 4) ϫ 10 4 cells/mL. Cytospin preparations were prepared and stained with Diff-Quik (Dade International, Miami, FL) and evaluated by light microscopy. BAL fluid differential counts were as follows: alveolar macrophages 94 Ϯ 3%, lymphocytes 4 Ϯ 2%, and neutrophils 1 Ϯ 1%. To ensure no contamination with platelets, the supernatant was then further centrifuged in a microfuge (23ЊC, 3 min), and the supernatant was aliquoted and frozen at Ϫ20ЊC until analysis.
Plasma
Venous blood was collected from the same individuals undergoing lavage just prior to the lavage procedure. Based on the knowledge that platelets contain VEGF (21, 22) , we collected the blood in glass tubes containing buffered 0.105 M Na citrate (Becton Dickinson, Franklin Lakes, NJ). The citrated blood was centrifuged at 500 ϫ g for 30 min, the supernatant removed, and further centrifuged in a microfuge (23ЊC, 3 min). The resulting supernatant was aliquoted and frozen at Ϫ20ЊC until analysis.
VEGF Levels
VEGF levels in lavage fluid and plasma were determined by ELISA (R&D Systems, Minneapolis, MN).
The dilution of ELF with the PBS used for lavage was corrected by the urea method described by Rennard et al. (20) . The urea concentration in lavage fluid and plasma was determined spectrophotometrically using a urea color reagent (Sigma, St. Louis, MO). The epithelial lining fluid concentration of VEGF was calculated by the formula: VEGF ELF ϭ VEGF BAL (Urea plasma /Urea BAL ).
Western Analysis
To assess the isoform of VEGF in ELF, the BAL fluid was concentrated on Centriprep devices with a 10,000 MW cutoff (Millipore, Bedford, MA). Proteins were assessed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis under reducing conditions on 12% gels. After the proteins were transferred to nitrocellulose membranes, Western blotting was performed with a primary goat anti-human affinity purified IgG polyclonal antibody, which recognizes all isoforms of human VEGF (0.1 mg/mL used at 1:250 dilution; R&D Systems). The secondary antibody was an affinity purified alkaline phosphatase-conjugated donkey anti-goat IgG (0.6 mg/mL used at a 1:10,000 dilution; Jackson ImmunoResearch, West Grove, PA). The signal was amplified by luminol (New England Nuclear) and chemiluminescence was detected by a brief exposure on X-OMAT film (Kodak, Rochester, NY).
Statistics
Group averages were expressed as mean Ϯ SEM. Differences of group means were compared with the Mann-Whitney U test. Spearman's rank correlation coefficients r was calculated to examine the relationship of plasma and ELF VEGF. These nonparametric statistics were calculated using Number Cruncher Statistical System (NCSS, Kaysville, UT). A p value Ͻ0.05 was considered significant.
Results and Discussion
VEGF was easily measurable in bronchoalveolar lavage fluid of all eight normal individuals evaluated, with an average concentration in lavage fluid of 104 Ϯ 41 pg/mL (Figure 1 ). Western analysis of VEGF proteins from concentrated BAL fluid from an additional three individuals demonstrated a predominant band which co-migrated with a purified recombinant human VEGF165 protein standard, suggesting that the predominant VEGF isoform in ELF is VEGF165 (Figure 2 ). Plasma levels of VEGF averaged 22 Ϯ 10 pg/mL (Figure 3 ), comparable to those reported by others when the plasma is collected in citrate to avoid contamination by platelet VEGF (21, 22) . Strikingly, when corrected for the dilution by the PBS used to collect the epithelial lining fluid, the levels of VEGF in respiratory ELF averaged 11,000 Ϯ 5000 pg/mL ELF, a level 500-fold greater than that in plasma of the same individuals significant correlation among the ELF and plasma VEGF levels among the same individuals ( Figure 4 ; r ϭ 0.46, p ϭ 0.19). It should be noted that sample size limitations do not preclude the possibility of (p Ͻ 0.0005). These data strongly suggest that local lung production of VEGF occurs and that the VEGF is compartmentalized on the respiratory epithelial surface. Consistent with this concept, there was no Figure 1 (j, k, l) . discovery of a correlation in specific patient age or sex subgroups as more individuals are evaluated.
Vascular Endothelial Growth Factor
The VEGF family includes structurally and functionally related polypeptides, designated VEGF-A through VEGF-E (23-25), of which VEGF-A (also called VEGF-1, but usually referred to as VEGF) is the prototypic member. VEGF is a heparin-binding glycoprotein, encoded by a 14 kb, 8 exon gene. VEGF exists as five different species, each having 121, 145, 165, 189, or 206 amino acids, created by alternative splicing of the VEGF primary mRNA transcript of these; VEGF121 and 165 are the dominant forms expressed. VEGF typically exists as homodimers of these isoforms, but the existence of VEGF heterodimers has been described (26) . VEGF was originally isolated from bovine pituitary tissue, but has been isolated from a variety of mammalian tissues, including cardiac myocytes and vascular smooth muscle cells. VEGF induces endothelial cell proliferation and directed migration, and promotes the formation of tube-like structures by endothelial cells cultured in collagen gels, reflective of its reported angiogenic potential in vivo (23) (24) (25) (26) . Although VEGF is primarily considered an angiogenic growth factor, it functions as a vascular permeability factor, and it can cause capillary leak, extravasation of fibrinogen, and the formation of a local fibrin lattice, which may serve as a template for endothelial growth and capillary formation (27) .
VEGF is considered to be an endothelial cellspecific mitogen because of the localization of its two high-affinity, tyrosine kinase receptors, flt-1 (fms-like-tyrosine kinase) and flk-1/KDR (fetal liver kinase/kinase domain region), to this cell type (flk-1 is the murine homologue of KDR) (1, 28) . The importance of VEGF in normal development is highlighted by the observation that homozygous deletion of the flt-1 or the flk-1 genes or the heterozygous deletion of VEGF in knockout mice is lethal, with abnormal fetal development (28) (29) (30) . Antibodies to VEGF negatively regulate VEGF function, and a murine anti-human monoclonal antibody has been shown to potently suppress angiogenesis and growth in a number of human tumor cell lines transplanted into nude mice and also to inhibit neovascularization in ischemic retinal disease (31, 32) .
Extensive data have accumulated linking VEGF and VEGF receptor expression with both normal biological processes, such as embryonic development, growth and differentiation, and wound healing, and pathologic processes, such as neoplasia, rheumatoid arthritis, and proliferative retinopathies (1-3,5,6 ). Hypoxic conditions in vitro and ischemia in vivo stimulate a transient increase in the expression of VEGF and its receptors flk-1 and flt-1 that typically peaks within one week after the introduction of angiogenic stimuli (14, 26, 33, 34) . This transcriptional upregulation appears to be regulated through a specific oxygen/heme protein response element in the VEGF gene (28) . Finally, VEGF has been shown to induce the expression and/or secretion of a number of proteins, including interstitial collagenase, urokinase-type activator, and tissue-type plasminogen activator. These proteins are potentially important in modulating the extracellular matrix and supporting endothelial cell invasion and sprouting (35) . Thus, the up-regulation of VEGF expression or the administration of VEGF may alone be sufficient to initiate and support angiogenesis. The critical native activity of this potent mediator, its relative endothelial selectivity (less selective mitogens such as FGF pose the potential risk of fibrosis and/or intimal hyperplasia), and the demonstrated ability of VEGF to induce angiogenesis in vivo have led to the use of VEGF as a therapeutic agent.
VEGF and Normal Lung Physiology
Consistent with our observations of high VEGF levels in adult ELF, increasing levels of VEGF as a function of time have been observed in tracheal aspirate fluid from preterm infants following delivery (36) . Potential cellular sources of VEGF in the lung include alveolar epithelium (13) (14) (15) (16) , airway epithelium (37, 38) , airway smooth muscle (37, 38) , and neutrophils (39) . The cells that are in direct contact with epithelial lining fluid are alveolar epithelium, alveolar macrophages, and to a much lesser extent, neutrophils, which normally comprise less than 1% of the mobile cells in the normal alveolus. Neutrophils produce VEGF when activated but little in the basal state (13, 39) . Therefore, the most likely dominant cellular source of the VEGF observed in normal individuals is the alveolar epithelium. In situ hybridization studies of human fetal lung tissue and animal lungs suggest that type II alveolar epithelial cells are the major source of VEGF in the lung (13) (14) (15) (16) . In human fetal lung tissue, VEGF expression is concentrated at the basement membranes of type II cells; it has been hypothesized that VEGF acts at this location to direct the assembly of the pulmonary vasculature (15) . It is likely that lung VEGF plays a role in normal maintenance and repair of the adult pulmonary circulation, where it is upregulated during recovery from hyperoxic injury in animal models (13) .
The identification of the VEGF165 as the major isoform in epithelial lining fluid is not surprising because the 189 and 206 isoforms are primarily bound to the extracellular matrix and the lower molecular mass. In addition, lack of heparin-binding domain of VEGF121 likely allows VEGF 121 to diffuse more readily (6, 16, (40) (41) (42) (43) . The molecular mass of VEGF165 is 19 kDa. Because VEGF165 forms homodimers, the VEGF165 on the respiratory epithelial surface has a molecular mass of 45 kDa (including glycosylation). Although the movement of VEGF may be restricted by the heparin-binding domain in the molecule's C-terminal portion, the and the alveolar epithelium genetically modified via an adenovirus vector results in both basolateral and apical secretion of the protein product of the transferred gene (57) , it has been observed that, in a mouse gene transfer model, acute overexpression of VEGF in the lung epithelium causes noncardiogenic pulmonary edema (18) . Because the alveolar epithelium normally represents a tight barrier to both fluid and macromolecular movement across it, the endothelium is likely to be protected from the high levels present in ELF. However, under conditions of acute injury to the alveolar epithelium, the epithelial barrier can be breached. In these circumstances, the alveolar endothelium would be directly exposed to the high levels of VEGF, which could secondarily contribute to an increase in endothelial permeability, a characteristic feature of acute lung injury. Interestingly, Beinert et al. (58, 59) have reported increased ELF VEGF in lung cancer patients undergoing radio-chemotherapy.
Although excess VEGF leads to pathological consequences, underexpression of VEGF also seems to have deleterious effects relevant to homeostasis of the pulmonary vasculature. These include an inadequate remodeling response to pulmonary hypertension (60) and the inability to respond appropriately to vasodilatory stimuli (61) (assuming VEGF controls eNOS). Recent data suggests that VEGF may be a necessary survival factor for endothelium (62) . VEGF also has anti-apoptotic effects in endothelium (63, 64) .
In summary, the present study demonstrates a remarkable compartmentalization of the potent VEGF molecule to the epithelial lining fluid of the lung. Although this likely serves a role in normal lung physiology as a reservoir for VEGF for the lung endothelium and possibly to recruit monocytes to the lung on a persistent basis, the high levels of VEGF on the respiratory epithelial surface also are a potential risk for the lung in that VEGF, if it reaches the alveolar endothelium in high levels, can induce pulmonary edema. In that context, one new approach for the treatment of acute, noncardiogenic pulmonary edema might be with strategies to inhibit VEGF, its receptors or downstream signal transduction pathways (18) . plasma molecule albumin with a molecular mass of 66 kDa compartmentalizes between plasma and respiratory epithelial lining fluid with a partition coefficient of 0.09 (ELF to plasma) (20) . Assuming the partition is similar for molecules with this mass compartmentalized to the epithelial surface of the lung, we would expect the ELF VEGF to serve as a reservoir with slow diffusion in the normal lung with the lung interstitium, slowly reaching the pulmonary endothelium. Precedent exists for locally produced protein to be highly concentrated in ELF relative to plasma. For example, Clara cell protein (CC16) a 16-17 kDa protein has been reported to be concentrated 5000-fold in rat ELF relative to plasma (44) . Polarized secretion of VEGF from alveolar epithelium has not been studied; however, other types of epithelium do exhibit polarized apical vs basal VEGF secretion (45, 46) . VEGF has important direct vasoactive effects (47, 48) . In the pulmonary circulation, nitric oxide, a potent and short-lived locally acting mediator, is responsible for endothelium-dependent vasodilation (49) . Nitric oxide production is determined by the activity of the enzyme endothelial nitric oxide synthase (eNOS), which produces NO by converting L-arginine to L-citrulline (50) . Regulation of eNOS protein occurs at both the transcriptional and posttranscriptional levels (51, 52) . Vascular endothelial growth factor up-regulates eNOS protein levels by several mechanisms (51, 52) , in addition to inducing activation of eNOS by phosphorylation (50) . Because VEGF is known to up-regulate eNOS, it is conceivable that VEGF may function locally in the lung to drive the continuous activation and/or expression of eNOS in the pulmonary endothelium, to maintain normal pulmonary circulatory homeostasis.
Although the expression of the flt-1 and flk-1 (KDR) VEGF receptors is primarily restricted to endothelium, blood monocytes also express the VEGF receptor flt-1 (53) and respond to VEGF as a chemotactic factor (53) . Therefore, another possible physiologic role for VEGF levels in ELF is to maintain a concentration gradient such that monocytes are continually recruited into the alveolar space from blood to replenish the pool of terminally differentiated alveolar macrophages. In this context, it is of interest that the levels of VEGF present in ELF far exceed the concentration of VEGF that is chemotactic for monocytes in the classic Boyden chamber assay (53) .
VEGF and Lung Pathophysiology
In the context of the known function of VEGF as a permeability factor, the obvious pathophysiologic role of VEGF in the lung is to induce pulmonary edema. The 500-fold higher than plasma levels of VEGF in respiratory ELF may be a "Damocles sword," poised to induce pulmonary edema if the tight epithelial barrier is breached. Because adenovirusmediated gene transfer to the alveolar epithelium markedly expresses the transferred gene (54) (55) (56) 
